Patents by Inventor Veronique Blanchard-Bregeon

Veronique Blanchard-Bregeon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • H3 receptor antagonist for use in the treatment of alzheimer's disease
    Patent number: 9789102
    Abstract: This disclosure relates to methods of using 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in a disease modifying therapy of Alzheimer's disease, other tauopathies and related neurodegenerative diseases.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: October 17, 2017
    Assignee: SANOFI
    Inventors: Pascal Barneoud, Veronique Blanchard-Bregeon, Veronique Mary, Jean Menager, Philippe Delay-Goyet, Mathilde Lopez-Grancha, Thomas Rooney, Nathalie Schussler
  • H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20160101099
    Abstract: This disclosure relates to methods of using 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in a disease modifying therapy of Alzheimer's disease, other tauopathies and related neurodegenerative diseases.
    Type: Application
    Filed: October 1, 2015
    Publication date: April 14, 2016
    Inventors: Pascal BARNEOUD, Veronique BLANCHARD-BREGEON, Veronique MARY, Jean MENAGER, Philippe DELAY-GOYET, Mathilde LOPEZ-GRANCHA, Thomas ROONEY, Nathalie SCHUSSLER
  • AN H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20150031893
    Abstract: This disclosure relates to methods of using 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in a disease modifying therapy of Alzheimer's disease, other tauopathies and related neurodegenerative diseases.
    Type: Application
    Filed: October 3, 2014
    Publication date: January 29, 2015
    Inventors: Pascal BARNEOUD, Veronique BLANCHARD-BREGEON, Veronique MARY, Jean MENAGER, Philippe DELAY-GOYET, Mathilde LOPEZ GRANCHA, Thomas ROONEY, Nathalie SCHUSSLER
  • Antibodies specific of the ?-amyloid peptides and their uses as diagnostic agents or drugs
    Patent number: 8343493
    Abstract: A monoclonal antibody which specifically binds to the N-terminal region of A?8-x peptide, x being included from 11 to 42, and recognizes neither A?1-40 nor A?1-42 and which presents a high affinity with respect to A?8-x peptide, such as determined by an immunological complex formation between the monoclonal antibody and the peptide A?8-x.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: January 1, 2013
    Assignees: Innogenetics N.V., INSERM (Institut National de la Sante et de la Recherche Medicale), Sanofi
    Inventors: Eugeen VanMechelen, Pierre Grognet, Nicolas Sergeant, Marie Gompel, Andre Delacourte, Luc Buee, Laurent Pradier, Veronique Blanchard-Bregeon
  • ANTIBODIES SPECIFIC OF THE BETA-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS
    Publication number: 20110059092
    Abstract: The present invention relates to a monoclonal antibody which specifically binds to the N-terminal region of A?8-x peptide, x being comprised from 11 to 42, and recognises neither A?1-40 nor A?1-42 and which presents a high affinity with respect to A?8-x peptide, such as determined by an immunological complex formation between the monoclonal antibody and the peptide A?8-x.
    Type: Application
    Filed: October 24, 2008
    Publication date: March 10, 2011
    Applicants: INNOGENETICS NV, SANOFI-AVENTIS
    Inventors: Eugeen Vanmechelen, Pierre Grognet, Nicolas Sergeant, Marie Gompel, Andre Delacourte, Luc Buee, Laurent Pradier, Veronique Blanchard-bregeon
  • Transgenic animals exhibiting major disorders related to Alzheimer's disease
    Patent number: 7700823
    Abstract: The present invention relates to nonhuman transgenic animals exhibiting major disorders related to Alzheimer's disease. The animals can be used for demonstrating compounds intended for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: October 1, 2004
    Date of Patent: April 20, 2010
    Assignee: Aventis Pharma S.A.
    Inventors: Caty Casas Louzao, Patrick Benoit, Laurent Pradier, Gunter Tremp, Jean-Michel Itier, Véronique Blanchard-Bregeon
  • Transgenic animals exhibiting major disorders related to Alzheimer's disease
    Publication number: 20050076400
    Abstract: The present invention relates to nonhuman transgenic animals exhibiting major disorders related to Alzheimer's disease. The animals can be used for demonstrating compounds intended for the treatment of Alzheimer's disease.
    Type: Application
    Filed: October 1, 2004
    Publication date: April 7, 2005
    Applicant: Aventis Pharma S. A.
    Inventors: Caty Casas Louzao, Patrick Benoit, Laurent Pradier, Gunter Tremp, Jean-Michel Itier, Veronique Blanchard-Bregeon
  • Combinations of riluzole and levodopa for the treatment of Parkinson's disease
    Patent number: 6387936
    Abstract: The invention concerns a combination of levodopa and riluzole or a pharmaceutically acceptable salt of said compound and the use of said combination for treating Parkinson Disease.
    Type: Grant
    Filed: October 24, 2000
    Date of Patent: May 14, 2002
    Assignee: Aventis Pharma S.A.
    Inventors: Véronique Blanchard-Bregeon, Assunta Imperato, Saliha Moussaoui, Marie-Carmen Obinu, Michel Reibaud